ClinicalTrials.gg
CompletedNCT00532779Updated Nov 21, 2014Results posted

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

A Phase 3 interventional study of Naltrexone SR 16 mg/Bupropion SR 360 mg /day and Naltrexone SR 32 mg/Bupropion SR 360 mg /day in Obesity and Overweight, sponsored by Orexigen Therapeutics, Inc. Completed at 34 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-21.

Sponsored by Orexigen Therapeutics, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,742
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Enrollment
2nd of 23
1,742 · median 67
Started
2007
with 4 others
Phase 3
6 of 23
none open now
Registered
4th of 23
by date
Lead sponsor
10 of 23
Orexigen Therapeutics, Inc

Among the 23 studies testing naltrexone in Obesity, this one is the 2nd largest by enrollment, is one of 5 that started in 2007, is one of 6 in phase 3, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.

Read the detailed description

Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of 2 doses of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects with uncomplicated obesity and in those with overweight/obesity and hypertension and/or dyslipidemia.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Obesity
  • Antiobesity agents
  • Antiobesity drugs
  • Overweight drug therapy
  • Obese drug therapy
  • Weight loss drug effects
  • Bupropion administration and dosage
  • Naltrexone administration and dosage
  • Double blind method
  • Combination drug therapy
  • Delayed action preparations
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female and male subjects, 18 to 65 years of age;
  • Have ≥30 and ≤45kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45kg/m² for subjects with obesity and controlled hypertension and/or dyslipidemia;
  • Normotensive (systolic ≤140 mm Hg; diastolic ≤90 mm Hg). Anti-hypertensive medications are allowed with the exception of alpha-adrenergic blockers and clonidine; medical regimen must be stable for at least 6 weeks prior to randomization;
  • Medications for treatment of dyslipidemia are allowed as long as medical regimen has been stable for at least 6 weeks prior to randomization;
  • Free of opioid medication for 7 days prior to randomization;
  • No abnormality of serum albumin, blood urea nitrogen, creatinine, , sodium, potassium, chloride, calcium or phosphorus;
  • (ALT) and aspartate aminotransferase (AST) within 2.5 x (ULN);
  • No clinically significant abnormality of hematocrit, white blood cell (WBC) count, white cell differential, or ;
  • Fasting glucose \< 126 mg/dL on no hypoglycemic agents, fasting triglycerides \<400 mg/dL;
  • No clinically significant abnormality on urinalysis;
  • TSH within normal limits or normal T3, if TSH is below normal limits;
  • Negative serum pregnancy test in women of ;
  • Negative urine drug screen;
  • IDS-SR scores \< 2 on items 5 (sadness), 6 (irritability), 7 (anxiety/tension) and 18 (suicidality), and IDS-SR total score \< 30;
  • Women of child bearing potential had to be non-lactating and agree to use effective throughout the study period and 30 days after discontinuation of study drug;
  • Able to comply with all required study procedures and schedule;
  • Able to speak and read English;
  • Willing and able to give written .

Exclusion criteria

Exclusion Criteria:

  • Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established Polycystic Ovary Syndrome);
  • Serious medical conditions (including but not limited to ongoing renal or hepatic insufficiency, Class III or IV congestive heart failure; myocardial infarction, history of angina pectoris, claudication, or acute limb ischemia within the previous 6 months; lifetime history of stroke);
  • History of within the previous 5 years with exception of non-melanoma skin cancer or surgically cured cervical cancer;
  • A lifetime history of serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, or anorexia nervosa;
  • Current serious psychiatric illness including severe personality disorder, (e.g. borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt, current active suicidal ideation, or recent hospitalization due to psychiatric illness;
  • A response to bipolar disorder questions indicating the presence of bipolar disorder;
  • In need of medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months prior to randomization;
  • History of drug or alcohol abuse or dependence (with the exception of nicotine dependence) within 1 year prior to study initiation;
  • Type 1 or Type 2 diabetes mellitus;
  • Screening with a interval by the method of Bazett (QTcB) >450 msec (men) and > 470 millisecond (msec) (women) or the presence of any cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities;
  • Excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer, anticonvulsant agents or agents for the treatment of Attention Deficit Disorder) with the exception of low dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over-the-counter dietary supplements or herbs with psychoactive, appetite or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral ; cholestyramine, cholestypol, Depo Provera®; smoking cessation agents; use of opioid or opioid-like medications, including analgesics and antitussives;
  • History of surgical or device (e.g., gastric banding) intervention for obesity;
  • History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures);
  • History of treatment with bupropion or naltrexone within the preceding 12 months;
  • History of or intolerance to bupropion or naltrexone;
  • Initiation or discontinuation of tobacco products including inhaled tobacco (such as cigarettes, cigars, pipes, etc), chewing tobacco or snuff in the 3 months prior to randomization or planned during study participation. Use of nicotine replacement products (nicotine gum, patch) during study participation was not allowed;
  • Use of drugs, herbs, or dietary supplements believed to significantly affect body weight or participation in a weight loss management program within one month prior to randomization;
  • Loss or gain of more than 4.0 kilograms within 3 months prior to randomization;
  • Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug;
  • Planned surgical procedure that can impact the conduct of the study;
  • Use of drug, device or procedure within the previous 30 days;
  • Participation in any previous clinical trial sponsored by Orexigen Therapeutics;
  • Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study;
  • Investigators, study personnel, sponsor representatives and their immediate families.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,742 participants (actual)

Study arms

  • Experimental
    NB16

    Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy

    Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day · Behavioral: Ancillary therapy

  • Experimental
    NB32

    Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy

    Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day · Behavioral: Ancillary therapy

  • Placebo comparator
    Placebo

    Placebo with ancillary therapy

    Drug: Placebo · Behavioral: Ancillary therapy

Interventions

  • DrugNaltrexone SR 16 mg/Bupropion SR 360 mg /day

    Drug page: Naltrexone

    Also known as: NB16

  • DrugNaltrexone SR 32 mg/Bupropion SR 360 mg /day

    Drug page: Naltrexone

    Also known as: NB32

  • DrugPlacebo
  • BehavioralAncillary therapy

    Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling

06

What researchers measure

Primary outcomes

  1. Co-primary: Body Weight- Mean Percent Change

    Time frame: Baseline, 56 weeks

  2. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

    Time frame: Baseline, 56 weeks

Secondary outcomes

  1. Body Weight- Proportion of Subjects With ≥10% Decrease

    Time frame: Baseline, 56 weeks

  2. Change in Waist Circumference

    Time frame: Baseline, 56 weeks

  3. Change in Fasting HDL Cholesterol Levels

    Time frame: Baseline, 56 weeks

  4. Change in Fasting Triglycerides Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  5. Change in IWQOL-Lite Total Scores

    IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

    Time frame: Baseline, 56 weeks

  6. Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  7. Change in Fasting Insulin Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  8. Change in Fasting Blood Glucose Levels

    Time frame: Baseline, 56 weeks

  9. Change in HOMA-IR Levels, Using Log-transformed Data

    HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

    Time frame: Baseline, 56 weeks

  10. Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

    Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

    Time frame: Baseline, 56 weeks

  11. Change in Fasting LDL Cholesterol Levels

    Time frame: Baseline, 56 weeks

  12. Change in Systolic Blood Pressure

    Time frame: Baseline, 56 weeks

  13. Change in Diastolic Blood Pressure

    Time frame: Baseline, 56 weeks

  14. Change in IDS-SR Total Scores

    IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

    Time frame: Baseline, 56 weeks

  15. Change in Food Craving Inventory Sweets Subscale Score

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 56 weeks

  16. Change in Food Craving Inventory Carbohydrates Subscale Score

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 56 weeks

07

Results

Posted Nov 21, 2014

Participant flow

Participant flow — Overall Study
MilestoneNB16NB32Placebo
Started578583581
Completed284296290
Not completed294287291
Withdrew: Adverse event12211256
Withdrew: Lost to follow-up766566
Withdrew: Withdrawal by subject636090
Withdrew: Lack of efficacy121240
Withdrew: Protocol violation597
Withdrew: Pregnancy253
Withdrew: Death010
Withdrew: Drug noncompliance, moved, other142329

Outcome measures

PrimaryCo-primary: Body Weight- Mean Percent Change
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percentage of body weight
Co-primary: Body Weight- Mean Percent Change
percentage of body weightNB16NB32Placebo
Co-primary: Body Weight- Mean Percent Change-5.00 ± 0.31-6.14 ± 0.31-1.33 ± 0.30
Statistical analysis
  • NB16 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -3.67 · 95% CI -4.50 to -2.85
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -4.81 · 95% CI -5.63 to -3.99
PrimaryCo-primary: Body Weight- Proportion of Subjects With ≥5% Decrease
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease
percentage of participantsNB16NB32Placebo
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease39.49 (35.08 to 43.91)47.98 (43.47 to 52.49)16.44 (13.22 to 19.65)
Statistical analysis
  • NB16 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.42 · 95% CI 2.52 to 4.63
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.86 · 95% CI 3.60 to 6.57
SecondaryBody Weight- Proportion of Subjects With ≥10% Decrease
Time frame:
Baseline, 56 weeks
Reported as:
Number · Percentage of participants
Body Weight- Proportion of Subjects With ≥10% Decrease
Percentage of participantsNB16NB32Placebo
Body Weight- Proportion of Subjects With ≥10% Decrease20.17 (16.55 to 23.79)24.63 (20.74 to 28.52)7.44 (5.16 to 9.71)
Statistical analysis
  • NB16 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.21 · 95% CI 2.14 to 4.81
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.19 · 95% CI 2.82 to 6.23
SecondaryChange in Waist Circumference
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · cm
Change in Waist Circumference
cmNB16NB32Placebo
Change in Waist Circumference-5.04 ± 0.43-6.24 ± 0.42-2.46 ± 0.43
Statistical analysis
  • NB16 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -2.58 · 95% CI -3.74 to -1.43
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -3.78 · 95% CI -4.93 to -2.64
SecondaryChange in Fasting HDL Cholesterol Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting HDL Cholesterol Levels
mg/dLNB16NB32Placebo
Change in Fasting HDL Cholesterol Levels3.36 ± 0.473.42 ± 0.45-0.06 ± 0.47
Statistical analysis
  • NB16 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 3.42 · 95% CI 2.17 to 4.66
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 3.48 · 95% CI 2.26 to 4.70
SecondaryChange in Fasting Triglycerides Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Triglycerides Levels, Using Log-transformed Data
percent changeNB16NB32Placebo
Change in Fasting Triglycerides Levels, Using Log-transformed Data-7.96 (-11.35 to -4.44)-12.69 (-15.79 to -9.47)-3.08 (-6.62 to 0.60)
Statistical analysis
  • NB16 vs Placebo · ANCOVA · p = =0.046 · Mean difference (net): -4.88
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -9.61
SecondaryChange in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in IWQOL-Lite Total Scores
units on a scaleNB16NB32Placebo
Change in IWQOL-Lite Total Scores11.68 ± 0.5412.69 ± 0.548.55 ± 0.51
Statistical analysis
  • NB16 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 3.13 · 95% CI 1.72 to 4.54
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 4.14 · 95% CI 2.73 to 5.56
SecondaryChange in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
percent changeNB16NB32Placebo
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data-28.02 (-34.09 to -21.39)-28.98 (-34.79 to -22.65)-16.66 (-23.68 to -9.00)
Statistical analysis
  • NB16 vs Placebo · ANCOVA · p = =0.016 · Mean difference (net): -11.36
  • NB32 vs Placebo · ANCOVA · p = =0.008 · Mean difference (net): -12.32
SecondaryChange in Fasting Insulin Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Insulin Levels, Using Log-transformed Data
percent changeNB16NB32Placebo
Change in Fasting Insulin Levels, Using Log-transformed Data-11.84 (-17.28 to -6.05)-17.14 (-21.96 to -12.02)-4.57 (-10.35 to 1.58)
Statistical analysis
  • NB16 vs Placebo · ANCOVA · p = =0.063 · Mean difference (net): -7.27
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -12.57
SecondaryChange in Fasting Blood Glucose Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting Blood Glucose Levels
mg/dLNB16NB32Placebo
Change in Fasting Blood Glucose Levels-2.39 ± 0.57-3.24 ± 0.55-1.30 ± 0.56
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): -1.09 · 95% CI -2.60 to 0.42
  • NB32 vs Placebo · ANCOVA · p = =0.010 · Mean difference (net): -1.94 · 95% CI -3.42 to -0.46
SecondaryChange in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in HOMA-IR Levels, Using Log-transformed Data
percent changeNB16NB32Placebo
Change in HOMA-IR Levels, Using Log-transformed Data-14.33 (-20.13 to -8.10)-20.19 (-25.26 to -14.78)-5.90 (-12.11 to 0.74)
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): -8.43
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -14.29
SecondaryChange in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire
units on a scaleNB16NB32Placebo
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire-12.49 ± 1.10-14.52 ± 1.09-8.68 ± 1.04
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): -3.81 · 95% CI -6.68 to -0.94
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -5.84 · 95% CI -8.71 to -2.98
SecondaryChange in Fasting LDL Cholesterol Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting LDL Cholesterol Levels
mg/dLNB16NB32Placebo
Change in Fasting LDL Cholesterol Levels-3.67 ± 1.21-4.41 ± 1.17-3.28 ± 1.20
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): -0.39 · 95% CI -3.62 to 2.84
  • NB32 vs Placebo · ANCOVA · p = 0.484 · Mean difference (net): -1.13 · 95% CI -4.29 to 2.04
SecondaryChange in Systolic Blood Pressure
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mm Hg
Change in Systolic Blood Pressure
mm HgNB16NB32Placebo
Change in Systolic Blood Pressure0.29 ± 0.40-0.11 ± 0.41-1.94 ± 0.39
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): 2.23 · 95% CI 1.16 to 3.30
  • NB32 vs Placebo · Mean difference (net): 1.83 · 95% CI 0.76 to 2.90
SecondaryChange in Diastolic Blood Pressure
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mm Hg
Change in Diastolic Blood Pressure
mm HgNB16NB32Placebo
Change in Diastolic Blood Pressure0.09 ± 0.290.04 ± 0.29-0.86 ± 0.28
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): 0.96 · 95% CI 0.19 to 1.73
  • NB32 vs Placebo · Mean difference (net): 0.90 · 95% CI 0.13 to 1.67
SecondaryChange in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in IDS-SR Total Scores
units on a scaleNB16NB32Placebo
Change in IDS-SR Total Scores0.02 ± 0.21-0.27 ± 0.21-0.72 ± 0.20
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): 0.74 · 95% CI 0.19 to 1.28
  • NB32 vs Placebo · Mean difference (net): 0.46 · 95% CI -0.09 to 1.00
SecondaryChange in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Sweets Subscale Score
units on a scaleNB16NB32Placebo
Change in Food Craving Inventory Sweets Subscale Score-2.08 ± 0.21-2.62 ± 0.21-2.77 ± 0.20
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): 0.69 · 95% CI 0.14 to 1.23
  • NB32 vs Placebo · Mean difference (net): 0.15 · 95% CI -0.40 to 0.69
SecondaryChange in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Carbohydrates Subscale Score
units on a scaleNB16NB32Placebo
Change in Food Craving Inventory Carbohydrates Subscale Score-1.85 ± 0.20-2.11 ± 0.20-1.84 ± 0.19
Statistical analysis
  • NB16 vs Placebo · Mean difference (net): -0.00 · 95% CI -0.53 to 0.53
  • NB32 vs Placebo · Mean difference (net): -0.27 · 95% CI -0.80 to 0.27

Adverse events

Collected over Baseline, 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NB16—9/569 (1.6%)345/569 (60.6%)
NB32—9/573 (1.6%)365/573 (63.7%)
Placebo—8/569 (1.4%)230/569 (40.4%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventNB16NB32Placebo
Pericardial effusionCardiac disorders0/5690/5731/569
Gastrointestinal haemorrhageGastrointestinal disorders1/5690/5730/569
Small intestinal obstructionGastrointestinal disorders1/5690/5730/569
Chest discomfortGeneral disorders0/5690/5731/569
Chest painGeneral disorders1/5691/5730/569
Non-cardiac chest painGeneral disorders0/5690/5731/569
Cholecystitis chronicHepatobiliary disorders1/5691/5730/569
CellulitisInfections and infestations0/5690/5731/569
DiverticulitisInfections and infestations1/5690/5730/569
GastroenteritisInfections and infestations0/5690/5731/569
Most frequent other events
Showing 10 of 12
Most frequent other events
EventNB16NB32Placebo
NauseaGastrointestinal disorders155/569171/57330/569
HeadacheNervous system disorders91/56979/57353/569
ConstipationGastrointestinal disorders90/56990/57332/569
Upper respiratory tract infectionInfections and infestations49/56957/57364/569
VomitingGastrointestinal disorders36/56956/57314/569
DizzinessNervous system disorders44/56954/57315/569
Dry mouthGastrointestinal disorders42/56943/57311/569
InsomniaPsychiatric disorders36/56943/57329/569
SinusitisInfections and infestations34/56930/57334/569
NasopharyngitisInfections and infestations32/56929/57331/569

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)NB16NB32PlaceboTotal
Mean44.35 ± 11.2544.41 ± 11.1443.66 ± 11.1444.14 ± 11.17
Sex: Female, Male
Sex: Female, Male(Participants)NB16NB32PlaceboTotal
Female4904964961482
Male888785260
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NB16NB32PlaceboTotal
American Indian or Alaska Native13181748
Asian46414
Native Hawaiian or Other Pacific Islander65415
Black or African American122106110338
White4274404401307
Other68620
Weight
Weight(kg)NB16NB32PlaceboTotal
Mean99.49 ± 14.7699.70 ± 15.8899.45 ± 14.3199.55 ± 14.99
BMI
BMI(kg/m^2)NB16NB32PlaceboTotal
Mean36.22 ± 4.2836.10 ± 4.3536.18 ± 4.0036.17 ± 4.21
08

Study locations

34 sites
  • Radiant Research
    Birmingham, Alabama 35209, United States
  • SelfCenter, PC
    Fairhope, Alabama 36532, United States
  • Radiant Research, Phoenix Southeast
    Chandler, Arizona 85225, United States
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • Advance Clinical Research Institute
    Orange, California 92869, United States
  • Scripps Clinic Del Mar
    San Diego, California 92130, United States
  • VA San Diego Healthcare System
    San Diego, California 92161, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • University Clinical Research
    Pembroke Pines, Florida 33024, United States
  • Georgia Clinical Research
    Atlanta, Georgia 30308, United States
  • CSRA Partners in Health, Inc
    Augusta, Georgia 30909, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Radiant Research
    Chicago, Illinois 60610, United States
  • Welborn Clinic
    Evansville, Indiana 47713, United States
  • Radiant Research Kansas City
    Overland Park, Kansas 66202, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Medical Research Institute
    Slidell, Louisiana 70458, United States
  • Health Trends Research, LLC
    Baltimore, Maryland 21209, United States
  • FutureCare Studies
    Springfield, Massachusetts 01103, United States
  • Center for Nutrition and Metabolic Disorders
    Reno, Nevada 89557, United States
  • Center for Nutrition and Preventive Medicine
    Charlotte, North Carolina 28211, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Central Ohio Nutrition Center, Inc.
    Columbus, Ohio 43213, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Summit Research Network (Oregon), Inc.
    Portland, Oregon 97210, United States
  • Internal Medicine Associates of Cordova
    Cordova, Tennessee 38018, United States
  • Jackson Clinic, PA
    Jackson, Tennessee 38305, United States
  • Covance Clinical Research Unit Austin
    Austin, Texas 78752, United States
  • Radiant Research
    Dallas, Texas 75231, United States
  • Baylor Endocrine Center
    Dallas, Texas 75246, United States
  • Radiant Research
    San Antonio, Texas 78217, United States
  • Oakwell Clinical Research
    San Antonio, Texas 78218, United States
09

References and documents

Publications

  • Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum In: Lancet. 2010 Aug 21;376(9741):594. Lancet. 2010 Oct 23;376(9750):1392. PubMed 20673995 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 5 years 6 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2007
First posted
Sep 20, 2007
Start
Oct 2007
Primary completionActual
May 2009
CompletionActual
May 2009
Results delay requested
Oct 31, 2012
Results first posted
Nov 21, 2014
Last update
Nov 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00532779
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Sep 20, 2007
Start date
Oct 2007
Primary completion
May 2009
Completion
May 2009
Results posted
Nov 21, 2014
Last update
Nov 21, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion